Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 4, 1999, Pages 541-548

  Wasilewski, Margaret M ^a   Johns, Don ^a   Sides, Gregory D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIRITHROMYCIN; ERYTHROMYCIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORAXELLA CATARRHALIS; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; VAGINITIS; VERTIGO;

EID: 0032959688     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.4.541     Document Type: Article

References (36)

1. Sides, G. D., Cerimele, B. J., Black, H. R., Busch U. & DeSante, K. A. (1993). Pharmacokinetics of dirithromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 65-75.
2. Counter, F. T., Ensminger, P. W., Preston, D. A., Wu, C. Y., Greene, J. M., Felty-Duckworth, A. M. et al. (1991). Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrobial Agents and Chemotherapy 35, 1116-26.
3. Bergogne-Berezin, E. (1993). Tissue distribution of dirithromycin: comparison with erythromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 77-87.
4. Kirst, H. A., Creemer, L. C., Paschal, J. W., Preston, D. A., Alborn, W. E., Counter, F. T. et al. (1995). Antimicrobial characterization and interrelationships of dirithromycin and epidirithromycin. Antimicrobial Agents and Chemotherapy 39, 1436-41.
5. DeSante, K. A. (1995). Human pharmacokinetics and bioavailability of dirithromycin. Drugs Today 31, 99-104.
6. Cazzola, M., Matera, M. G., Tufano, M. A., Polverino, M., Catalanotti, P., Varanese, L. et al. (1994). Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. Pulmonary Pharmacology 7, 377-81.
7. Baughman, R. P., DeSante, K. A., Lanier, T. L., Conforti, P. M. & Sides, G. D. (1994). The penetration of dirithromycin into bronchoalveolar lavage fluid and alveolar macrophages. Journal of Antimicrobial Chemotherapy 33, 1045-50.
8. Yu, K. W. & Neu, H. C. (1990). In vitro activity of dirithromycin (LY237216) compared with activities of other macrolide antibiotics. Antimicrobial Agents and Chemotherapy 34, 1839-42.
9. Liippo, K., Tala, E., Puolijoki, H., Bruckner, O. J., Rodrig, J. & Smits, J. P. (1994). A comparative study of dirithromycin and erythromycin in bacterial pneumonia. Journal of Infection 28, 131-9.
10. Rennie, K. A., Prasad, E. S. & Wenman, W. M. (1994). In vitro activity of dirithromycin, a new macrolide antibiotic, against Mycoplasma species. Diagnostic Microbiology and Infectious Disease 20, 57-9.
11. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. (1995). In-vitro activity of dirithromycin, erythromycylamine and erythromycin against Chlamydia pneumoniae. Abstract from the General Meeting of the American Society for Microbiology 95, 146.
12. National Committee for Clinical Laboratory Standards. (1994). Performance Standards for Antimicrobial Disc Susceptibility Tests -Fifth Edition: Approved Standard M2-A5. NCCLS, Villanova, PA.
13. Dilorenzo, P., Shupbach, C., Salisbury, J., Ogbonnaya, K., Ruoff, G. & Davenport, C. (1993). Dirithromycin (D) 5 days versus erythromycin base (E) 7 days in skin and soft tissue infections. In Programme and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 402. American Society for Microbiology, Washington, DC.
14. Derriennic, M. & Escande, J. P. (1993). Dirithromycin in the treatment of skin and skin structure infections. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 159-68.
15. Derriennic, M., Conforti, P. M. & Sides, G. D. (1993). Dirithromycin in the treatment of streptococcal pharyngitis. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 89-95.
16. Watkins, V. S., Smietana, M., Conforti, P. M., Sides, G. D. & Huck, W. (1997). Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis. Antimicrobial Agents and Chemotherapy 41, 72-5.
17. Sides, G. D. (1993). Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 131-8.
18. Gaillat, J. (1993). A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of bronchitis. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 139-51.
19. Jacobson, K. (1993). Clinical efficacy of dirithromycin in pneumonia. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 121-9.
20. McCarty, J. M., Huck, W., Guthrie, E. H., Smietana, M., Adams, K. B. & Conforti, P. M. (1993). Dirithromycin (D) vs penicillin VK (P) in the treatment of streptococcal pharyngitis and-or tonsillitis. In Programme and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993, Abstract 399. American Society for Microbiology, Washington, DC.
21. Makuch, R. & Simon, R. (1978). Size requirements for evaluating a conservative therapy. Cancer Treatment Report 62, 1037-40.
22. DerSimonian, R. & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-88.
23. Berlin, J. A., Laird, N. M., Sacks, H. S. & Chalmers, T. C. (1989). A comparison of statistical methods for combining event rates from clinical trials. Statistics in Medicine 8, 141-51.
24. Leroyer, C., Boussac, J., Lode, H., Smits, J. P. & Sides, G. D. (1995). A comparison of 5 days of dirithromycin and 7 days of roxithromycin in acute bacterial exacerbation of chronic bronchitis. Immunology and Infectious Diseases 5, 149-55.
25. Periti, P., Mazzei, T., Mini, E. & Novelli, A. (1993). Adverse effects of macrolide antibacterials. Drug Safety 9, 346-64.
26. Ruef, C., Blaser, J., Maurer, P., Keller, H. & Follath, F. (1996). Miscellaneous antibiotics. In Meyler's Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interaction, 13th edn (Dukes, M. N. G., Ed.), pp. 734-44. Excerpta Medica, Amsterdam.
27. Sides, G. D. & Conforti, P. M. (1993). Safety profile of dirithromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 175-85.
28. Neftel, K. A., Zoppi, M., Cerny, A. & Cottagnoud, P. (1996). Reactions typically shared by more than one class of β-lactam antibiotics. In Meyler's Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interactions, 13th edn (Dukes, M. N. G., Ed.), pp. 678-91. Excerpta Medica, Amsterdam.
29. Lindstrom, T. D., Hanssen, B. R. & Wrighton, S. A. (1991). Relative cytochrome P-450 mi-complex formation by dirithromycin and other macrolides in rat and human liver. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstract 519. American Society for Microbiology, Washington, DC.
30. Lindstrom, T. D., Hanssen, B. R. & Wrighton, S. A. (1993). Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrobial Agents and Chemotherapy 37, 265-9.
31. Periti, P., Mazzei, T., Mini, E. & Novelli, A. (1992). Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 23, 106-31.
32. Wermeling, D. P., Chandler, M. H. H., Sides, G. D., Collins, D. & Muse, K. N. (1995). Dirithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstetrics and Gynecology 86, 78-84.
33. Bachmann, K., Nunlee, M., Martin, M., Sullivan, T., Jauregui, L., DeSante, K. et al. (1990). Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin. Journal of Clinical Pharmacology 30, 1001-5.
34. Bachmann, K., Jauregui, L., Sides, G. & Sullivan, T. J. (1993). Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. Journal of Clinical Pharmacology 33, 861-5.
35. Bachmann, K., Sullivan, T. J., Reese, J. H., Miller, K., Scott, M. & Jauregui, L. (1994). The pharmacokinetics of oral cyclosporine A are not affected by dirithromycin. In Programme and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract A7. American Society for Microbiology, Washington, DC.
36. Bachmann, K., Sullivan, T. J., Reese, J. H., Jauregui, L., Miller, K., Scott, M. et al. (1995). The influence of dirithromycin on the pharmacokinetics of cyclosporine in healthy subjects and in renal transplant patients. American Journal of Therapeutics 2, 490-8.